Molecules evolved
in nature

ATYR1923 HEALTHY SUBJECTS SINGLE ASCENDING DOSE TRIAL: PHASE 1

In the fourth quarter of 2017, we initiated a first-in-human, randomized, double-blind, placebo-controlled study. The Phase 1 study is designed to investigate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous ATYR1923 in healthy volunteers. Subjects will be randomized to one of six cohorts and receive a single infusion of ATYR1923 or placebo.

Top-line results are expected in 2Q 2018.
 
Anzctr.org.au

© 2007 - 2018   aTyr Pharma.   Legal   Privacy Policy